Glyceraldehyde-3-phosphate dehydrogenase is overexpressed in colorectal cancer onset

dc.contributor.authorTarrado Castellarnau, Míriam Neus
dc.contributor.authorDiaz Moralli, Santiago
dc.contributor.authorPolat, Ibrahim H.
dc.contributor.authorSanz Pamplona, Rebeca
dc.contributor.authorAlenda, Cristina
dc.contributor.authorMoreno Aguado, Víctor
dc.contributor.authorCastells Garangou, Antoni
dc.contributor.authorCascante i Serratosa, Marta
dc.date.accessioned2018-03-07T16:11:48Z
dc.date.available2018-03-07T16:11:48Z
dc.date.issued2017-06-09
dc.date.updated2018-03-07T16:11:49Z
dc.description.abstractBackground Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is an essential regulator of glycolysis used as a housekeeping marker for gene/protein normalisation. Given the pivotal role of GAPDH in tumour metabolism, our aim was to correlate its protein expression with tumour staging and prognosis of colorectal cancer. Methods GAPDH expression was immunohistochemically analysed in tumour tissues from 62 colorectal cancer (CRC) patients, and validated at mRNA level in an independent dataset comprising 98 paired stage II CRC and normal samples. Staining quantification was performed by computational image analysis, and correlations between GAPDH expression and tumour progression stage were assessed. Gene expression profiling was performed using Affymetrix microarrays. Probability of patient survival and disease-free survival were analysed by the univariate product-limit method of Kaplan-Meier. Groups were compared using Kruskal-Wallis tests. Results Overexpression of GAPDH is positively associated with early stage tumours without regional lymph node and distant metastases involved. These results were reinforced by those obtained at mRNA level. Conclusion Studying the role of GAPDH in malignant transformation can shed new light on the understanding of tumour onset and lead to the design of more efficient personalised therapies.
dc.format.extent9 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec673696
dc.identifier.issn2396-832X
dc.identifier.urihttps://hdl.handle.net/2445/120518
dc.language.isoeng
dc.publisherBioMed Central
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1186/s41231-017-0015-7
dc.relation.ispartofTranslational Medicine Communications, 2017, vol. 2, num. 6, p. 1-9
dc.relation.urihttps://doi.org/10.1186/s41231-017-0015-7
dc.rightscc-by (c) Tarrado Castellarnau, Míriam et al., 2017
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es
dc.sourceArticles publicats en revistes (Bioquímica i Biomedicina Molecular)
dc.subject.classificationCàncer colorectal
dc.subject.classificationEnzims
dc.subject.otherColorectal cancer
dc.subject.otherEnzymes
dc.titleGlyceraldehyde-3-phosphate dehydrogenase is overexpressed in colorectal cancer onset
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
673696.pdf
Mida:
2.87 MB
Format:
Adobe Portable Document Format